Displaying 21 - 30 of 243
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Peking University, Institute of Biomedical Engineering at Chinese Academy of Medical College
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR)
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: University of Washington
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Subdermal
Developer: Murdoch University
Development Stage: Prototype Development
Development Phase: Discovery and Early Development
Alternative Name: BDADs
User: Female, Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Focused Scientific, University of Washington
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Bromodomain Testis Associated, Cancer/Testis Antigen 9, Bromodomain Testis-Specific Protein, Bromodomain, Testis-Specific, RING3-Like Protein, CT9, SPGF21, BRD6
Target
User: Male
Hormonal: No
Delivery Method: Injectable, Oral
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Male
Hormonal: No
Delivery Method: Oral
Developer: Bar-Ilan University
Development Stage: Compound ID/Selection
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Gel
Developer: ReProtect Inc.
Development Stage: Phase III
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Calcium Binding Tyrosine Phosphorylation Regulated, Cancer/Testis Antigen 88, Calcium-Binding Tyrosine Phosphorylation-Regulated Protein, Testis-Specific Calcium-Binding Protein CBP86, Calcium-Binding Protein 86, Fibrousheathin II, Fibrousheathin-2, CBP86, FSP-2, CT88, FSP2
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Development Phase: Discovery and Early Development
Alternative Name: Epididymal Calchlorin
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Injectable
Developer: Parsemus Foundation
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 61 - 70 of 70
User: Female
Hormonal: No
Developer: Rutgers University
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Other
Development Stage: Lead Optimization
Target
User: Male
Hormonal: No
Developer: Baylor College of Medicine, NICHD
Development Stage: Target Validation
Alternative Name: RISUG in the Fallopian Tube
User: Female
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Fallopian Tube
Developer: Indian Institute of Technology, Kharagpur
Development Stage: Prototype Development
Alternative Name: Tripterygium wilfordii derivatives, including triptolide
User: Male
Hormonal: No
Developer: WHO, University of California at Los Angeles
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: FHI 360, GE Healthcare
Development Stage: Prototype Development
User: Female
Hormonal: Yes
Delivery Method: Vaginal, Other
Developer: University of Texas Health Science Center at San Antonio
Development Stage: Lead Optimization
Alternative Name: WEE1 HOMOLOG 2; WEE1B; WEE2 Kinase
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, University of Minnesota
Development Stage: Lead Optimization
Alternative Name: Miglustat; N-butyldeoxynojirimycin (NB-DNJ)
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Oral
Developer: University of Washington, Oxford GlycoSciences
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: University of Nairobi
Development Stage: Lead Optimization

Pages

Displaying 31 - 40 of 121
Alternative Name: Estetrol (E4) + Drospirenone (DRSP) Combined Pill
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: Mithra
Development Stage: Phase III
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Hera Health Solutions
Development Stage: Pre-clinical
Alternative Name: EVE-106; EVE106; ethinylestradiol prodrugs
User: Female
Hormonal: Yes
Developer: Evestra, Inc.
Development Stage: Pre-clinical
Alternative Name: Etonogestrel (ENG) + Ethinyl Estradiol (EE) Vaginal Ring; EVE112
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Evestra, Inc., Gedeon Richter Plc.
Development Stage: Phase III
Alternative Name: Antiestrogen ICI 182780; Fulvestrant
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Development Stage: Pre-clinical
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: Femasys Inc
Development Stage: Phase I
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Injectable
Developer: University of Washington, Focused Scientific
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Delivery Method: Injectable
Developer: University of Mumbai
Development Stage: Pre-clinical
Alternative Name: Single Rod GES Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR), Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Phase III
Alternative Name: GES VR
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Vaginal Ring
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR), Shanghai Dahua Pharmaceuticals, Ltd.
Development Stage: Pre-clinical

Pages

Displaying 31 - 40 of 52
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Innova Quality S.A.S
Development Stage: Marketed
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Allergan
Development Stage: Regulatory
Alternative Name: Woman's Condom (WC)
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Shanghai Dahua Medical Apparatus Co., Ltd, PATH
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: Regulatory
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Helm Pharmaceuticals, Fresenius Kabi
Development Stage: Marketed
Alternative Name: Amphora® Gel, lactic acid, citric acid, and potassium bitartrate
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Evofem Biosciences, Inc.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Tianjin Condombao Medical Polyurethane Tech. Co. Ltd
Development Stage: SRA/WHO PQ Approved
Alternative Name: Pregna PPIUD T Cu 380A
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Pregna International Limited
Development Stage: SRA/WHO PQ Approved
Alternative Name: Progestin Vaginal Ring (PVR)
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Population Council, Grunenthal
Development Stage: Marketed
Alternative Name: VA w.o.w.
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: HLL Lifecare Limited, IXu LLC
Development Stage: SRA/WHO PQ Approved

Pages

CSV